A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.

Robyn T DomsicThomas A MedsgerShiyao GaoMaureen LaffoonSuiyuan HuangStephen WisniewskiCathie SpinoVirginia SteenRobert LafyatisDinesh Khanna

Published in: Rheumatology (Oxford, England) (2022)

Adjustment for both RNAP3 and TFR predicts mRSS trajectory and diminished the mRSS decline in ASSET placebo group, and identified significant differences in CRISS. RNAP3, particularly, is a stratification or enrichment approach to improve early diffuse SSc trial design.

Keyphrases

phase iii
low grade
clinical trial
systemic sclerosis
study protocol
randomized controlled trial
double blind
idiopathic pulmonary fibrosis
anterior cruciate ligament reconstruction